Biotech company (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and tribulations in this period, however. And in the past three years, the stock is down by a whopping 94%.
If Novavax can mount a comeback, now may be as good a time as any to press the buy button while its shares are changing hands for just about $5.46 apiece.
Or perhaps Novavax hasn't hit rock bottom yet and will continue to see its share price plunge. Which scenario is more likely? Let's dig in and find out.
Source Fool.com